{"id":742242,"date":"2012-03-05T08:30:00","date_gmt":"2012-03-05T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/"},"modified":"2023-03-22T00:04:25","modified_gmt":"2023-03-22T04:04:25","slug":"mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/","title":{"rendered":"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial"},"content":{"rendered":"<p class=\"bwalignc\">       Company Plans to File NDAs for Ragweed and Grass AITs in 2013     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        today announced the results from a Phase III clinical study of its        investigational allergy immunotherapy tablet (AIT) for ragweed pollen.        The study results showed that the use of ragweed AIT significantly        reduced the total combined score that measured nasal and eye symptoms        and use of rescue allergy medicines, compared to placebo, in        ragweed-allergic adults with or without asthma. The study was conducted        during peak ragweed pollen season. These data were presented at the        American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting        in Orlando.     <\/p>\n<p>       Merck&#8217;s AIT is an investigational, dissolvable oral tablet designed to        treat the underlying cause of allergies, and is being studied to        determine whether AIT may help to prevent allergy symptoms by generating        an immune response to protect against targeted allergens. The company is        investigating disease-modifying AITs for the treatment of allergies        caused by ragweed pollen, grass pollen and house dust mites. Merck has        partnered with ALK-Abello to develop AITs to treat these allergens in        North America and plans to file New Drug Applications (NDAs) for its        ragweed and grass AITs with the U.S. Food and Drug Administration (FDA)        in 2013.     <\/p>\n<p>       \u201cMerck is pleased that patients who took its AIT in this study        experienced a significant reduction in the nasal and eye symptoms caused        by ragweed allergies, and these positive results are an important step        in the development of this investigational therapy,\u201d said Rupert Vessey,        M.D., Ph.D, senior vice president and franchise head, Respiratory &amp;        Immunology, Merck Research Laboratories. \u201cWe are committed to providing        physicians and patients with a broad range of treatment options for        allergies and other respiratory diseases.\u201d     <\/p>\n<p>       Additional results from this Phase III study will be presented at the        AAAAI meeting in an oral presentation titled, \u201cRagweed Allergy        Immunotherapy Tablet Reduces Nasal and Ocular Symptoms of Allergic        Rhinoconjunctivitis Over the Peak Ragweed Pollen Season in North        America\u201d on March 6, 2012, 2 p.m. EST. A second, pivotal Phase III study        of similar design with ragweed AIT in 784 patients was also presented at        AAAAI.     <\/p>\n<p>       <b>Study Design<\/b>     <\/p>\n<p>       This multicenter, double-blind, randomized, placebo-controlled, parallel        group Phase III trial was designed to assess the efficacy and safety of        two doses of ragweed AIT. The study involved 565 adults who were 18 to        50 years old with ragweed-induced allergic rhinoconjunctivitis, with or        without asthma. The majority of these patients (85 percent) were        sensitive to multiple allergens. Patients were randomized to receive a        once-daily tablet of <i>Ambrosia artemisiifolia<\/i> (ragweed) allergen        extract at a dose of 6 Amb a 1-U or 12 Amb a 1-U or placebo for        approximately 16 weeks prior to and throughout the ragweed pollen        season, for a total treatment period of 52 weeks.     <\/p>\n<p>       During ragweed pollen season, patients recorded their symptoms and        rescue medication use daily in electronic diaries. The primary efficacy        assessment was total combined score, which was the sum of the daily        symptom score and the daily medication score averaged over the peak        ragweed pollen season (peak season was defined as the 15 consecutive        days with the highest 15-day moving average pollen count). The daily        symptom score consisted of daily ratings of four nasal symptoms (runny        nose, blocked nose, sneezing, and itchy nose) and two eye symptoms        (gritty eyes and watery eyes) on a scale from zero (no symptoms) to        three (severe symptoms), and the daily medication score assigned a score        based upon the type and amount of rescue medication used each day. The        safety profile of the study drug was monitored via adverse event (AE)        reporting, as well as by an external data and safety monitoring        committee.     <\/p>\n<p>       <b>Study Results<\/b>     <\/p>\n<p>       During peak ragweed season, patients treated with ragweed AIT 12 Amb a        1-U or AIT 6 Amb a 1-U showed 27 percent and 21 percent reductions in        total combined score, respectively, relative to placebo (p=.0002 and        p=.0039). Specifically, both doses of ragweed AIT resulted in        significant reductions in daily symptom score relative to placebo during        peak ragweed season (17 percent for AIT 12 Amb a 1-U, p=.0144; and 14        percent for AIT 6 Amb a 1-U, p=.0472). Ragweed AIT 12 Amb a 1-U and AIT        6 Amb a 1-U also yielded 45 percent and 34 percent reductions in daily        medication score, respectively, relative to placebo (p=.0001 and        p=.0039) during peak ragweed pollen season, a time when rescue        medications are expected to be utilized most.     <\/p>\n<p>       The most frequently reported treatment-related AEs were itchiness of the        mouth and ear and throat irritation. Two patients received epinephrine        during the course of the study. There were no reports of death, systemic        allergic reactions or life-threatening events over 52 weeks.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50190989&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=dcbb360c0d9d1ee9890adad5f1101cb9\" rel=\"noopener\">vip2-msd.com\/merckcom-migrated<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the United States and internationally and the exposure to        litigation and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50190989&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=b4b12116e1e6066fdf48ad93a0f03a3b\" rel=\"noopener\">www.sec.gov<\/a>).     <\/p>\n<\/p>\n<p><p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>Lesley        Brown, 267-305-3545<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen. The study results showed that the use of ragweed AIT significantly reduced the total combined score that measured nasal and eye symptoms and use of rescue allergy medicines, compared to placebo, in ragweed-allergic adults with or without asthma. The study was conducted during peak ragweed pollen season. These data were presented at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting in Orlando. Merck&#8217;s AIT is an investigational, dissolvable oral tablet designed to treat the underlying cause of allergies, and is being studied to determine whether AIT may help to prevent allergy symptoms by generating an immune response to protect against targeted allergens. The company is investigating disease-modifying AITs for the treatment of allergies caused by<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742242","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen. The study results showed that the use of ragweed AIT significantly reduced the total combined score that measured nasal and eye symptoms and use of rescue allergy medicines, compared to placebo, in ragweed-allergic adults with or without asthma. The study was conducted during peak ragweed pollen season. These data were presented at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting in Orlando. Merck&#039;s AIT is an investigational, dissolvable oral tablet designed to treat the underlying cause of allergies, and is being studied to determine whether AIT may help to prevent allergy symptoms by generating an immune response to protect against targeted allergens. The company is investigating disease-modifying AITs for the treatment of allergies caused by\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\\\/\",\"name\":\"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2012-03-05T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen. The study results showed that the use of ragweed AIT significantly reduced the total combined score that measured nasal and eye symptoms and use of rescue allergy medicines, compared to placebo, in ragweed-allergic adults with or without asthma. The study was conducted during peak ragweed pollen season. These data were presented at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting in Orlando. Merck's AIT is an investigational, dissolvable oral tablet designed to treat the underlying cause of allergies, and is being studied to determine whether AIT may help to prevent allergy symptoms by generating an immune response to protect against targeted allergens. The company is investigating disease-modifying AITs for the treatment of allergies caused by","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:25+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/","name":"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2012-03-05T08:30:00+00:00","dateModified":"2023-03-22T04:04:25+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2a56e9d5-b5f7-46a7-8c0c-7d7e10dd7098","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Investigational-Allergy-Immunotherapy-Tablet-AIT-Significantly-Reduced-the-Combination-of-Ragweed-Allergy-Symptoms-and-Medicat-LGU7G.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742242\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742242"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}